July 29, 2025

Chemo's Impact on Brain Explored

Neuroimaging detects reduced grey matter in multiple brain regions among breast cancer patients after chemotherapy, raising concern for long-term cognitive risks.

Conexiant

July 24, 2025

Intranasal Insulin Reaches Brain in First Human PET Study

Researchers visualize how insulin travels from the nose to the brain using PET scans, uncovering differences in uptake based on cognition, blood pressure, and sex.

Conexiant

July 01, 2025

Stem Cell Therapy Shows T1D Reversal Potential

A new stem cell–derived islet therapy showed insulin independence, restored beta-cell function, and prevented severe hypoglycemia in type 1 diabetes, based on interim results presented at the ADA’s 85th Scientific Sessions.

Conexiant

June 10, 2025

Does Combination Therapy Improve Albuminuria?

Finerenone plus empagliflozin reduced urinary albumin-to-creatinine ratio by 29% to 32% more than either drug alone in patients with chronic kidney disease and type 2 diabetes.

Conexiant

April 25, 2025

Head and Neck, Breast, Lung and Survivorship Studies Headline Dana-Farber Research at AACR Annual Meeting 2025

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.

Dana-Farber

June 03, 2025

Phytosterols May Shield Against Diabetes, CVD

Large Harvard study shows higher phytosterol intake, particularly beta-sitosterol, reduces type 2 diabetes and cardiovascular disease risk by up to 9%.

Conexiant

May 30, 2025

Major Medical Societies Issue GLP-1 Nutrition Guidelines

New advisory addresses nutritional challenges and side effects for obesity treatment

Conexiant

January 13, 2025

Dana-Farber and Gustave Roussy Announce 2025 Transatlantic Exchange Scientific Program to Focus on Radioligand Therapy

Dana-Farber Cancer Institute and Gustave Roussy (Grand Paris, Villejuif, France) have announced that the Fourth Transatlantic Exchange in Oncology Conference topic will be “Radiopharmaceutical Therapy Meets Oncology.”

Dana-Farber

May 06, 2025

Shorter Prostate Radiotherapy Proves Long-Term Match

Two-week radiation treatment for localized prostate cancer delivers equivalent 10-year outcomes to standard 8-week course in a clinical trial.

Conexiant